Active — Not RecruitingPhase 3

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

United States200 participantsStarted 2019-12-23

Plain-language summary

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Completion of a qualifying zilucoplan study Exclusion Criteria: * With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)

What they're measuring

Incidence of treatment-emergent adverse events (TEAEs)

Timeframe: From Baseline (Day 1) to Safety Follow-Up Visit (up to 36 months)

Trial details

NCT IDNCT04225871

SponsorUCB Biopharma SRL

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06-02

View on ClinicalTrials.gov More Generalized Myasthenia Gravis trials